Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

Documenti analoghi

• Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
  di: Weisel, Katja C., et al.
  Pubblicazione: (2016)
• Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
  di: San Miguel, Jesus F., et al.
  Pubblicazione: (2015)
• Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
  di: Dimopoulos, Meletios A., et al.
  Pubblicazione: (2016)
• Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
  di: Dimopoulos, Meletios A., et al.
  Pubblicazione: (2015)
• Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
  di: Dimopoulos, Meletios, et al.
  Pubblicazione: (2020)